Local view for "http://purl.org/linkedpolitics/eu/plenary/2016-03-09-Speech-3-212-375"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20160309.22.3-212-375"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spoken text |
"Many factors may influence to what extent medicines are available and accessible to the populations of developing countries. Numerous important factors come to play to determine price of medicines: taxes and import tariffs, distribution mark—ups, lack of an efficient procurement system, etc.
Scientific and technological innovation has significantly improved the treatment of human diseases. Intellectual property stimulates pharmaceutical companies to invest money to develop and produce new and better medicines. Bringing a medicine to market is a long and complex process that is very costly and takes many years to complete. Without the prospect of return on their investments, pharmaceutical companies will not allocate large budgets to more research and development. Patent protection can lead to higher prices by delaying the supply of cheaper generic alternatives. Hence, the argument is often made that patents on medicines restrict access to treatment for citizens in low—income developing countries. However, developing countries are increasingly using patents to protect their innovative companies’ efforts and help them compete more effectively on global markets.
The EU seeks to strike the right balance between the need to promote and finance the research of new and better medicines and to ensure that medicines are accessible to those in need."@en1
|
| lpv:spokenAs | |
| lpv:unclassifiedMetadata |
Named graphs describing this resource:
The resource appears as object in 2 triples